Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6NSCLC 5Respiratory Tract Neoplasms 1Lung Neoplasms 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1Bronchial Neoplasms 1Advanced Non-small Cell Lung Cancer 1Advanced NSCLC Patients With T790M 1Advanced NSCLC 1Advanced Lung Cancer 1

Interventions

Docetaxel 4pembrolizumab 2Carboplatin 2tislelizumab 1nazartinib 1lenvatinib 1cemiplimab 1aflutinib 1abivertinib 1Rosuvastatin Calcium 1Platinum Compounds 1Pemetrexed 1Nivolumab 1Midazolam 1Gefitinib 1Food 1Esomeprazole 1Dabigatran 1Cisplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Non-small Cell Lung Cancer × aflutinib × Clear all
NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1 Recruiting
288 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡